Eli Lilly and Company

LLYNYSE

$1,294.35

Last price · USD

Market cap: $1.16T
P/E: 56.4x
EV / EBITDA: 37.8x
P/S: 17.8x
FCF yield: 0.8%
Div. yield: 0.46%

Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.

Eli Lilly and Company balance sheet

Annual · USD millions except per-share data · 45 lines

Fiscal year	2025latest	2024	2023	2022	2021	CAGR
Current assets
Cash & cash equivalents	7,163	3,268	2,819	2,067	3,819	+17.0%
Short-term investments	105	155	109	145	90	+3.9%
Cash & short-term investments	7,268	3,423	2,928	2,212	3,909	+16.8%
Net receivables	20,155	13,275	11,336	8,559	8,127	+25.5%
Accounts receivable	17,760	11,006	9,091	6,896	6,673	+27.7%
Other receivables	2,395	2,270	2,246	1,663	1,454	+13.3%
Inventory	13,744	7,589	5,773	4,310	3,886	+37.1%
Prepaids	14,315	8,341	5,541	2,947	2,531	+54.2%
Other current assets	147	111	150	7	0	—
Total current assets	55,629	32,740	25,727	18,035	18,452	+31.8%
Non-current assets
Property, plant & equipment (net)	24,675	17,102	12,914	10,144	8,985	+28.7%
Goodwill	5,898	5,770	4,940	4,073	3,892	+11.0%
Intangible assets	6,521	6,166	6,907	7,207	7,692	-4.0%
Goodwill & intangible assets	12,419	11,937	11,846	11,280	11,584	+1.8%
Long-term investments	2,802	3,216	3,052	2,902	3,213	-3.4%
Tax assets	9,959	8,001	5,477	2,793	2,489	+41.4%
Other non-current assets	6,992	5,720	4,990	4,337	4,083	+14.4%
Total non-current assets	56,847	45,975	38,279	31,455	30,354	+17.0%
Total assets	112,476	78,715	64,006	49,490	48,806	+23.2%
Current liabilities
Accounts payable	5,379	3,229	2,599	1,931	1,671	+34.0%
Other payables	0	1,346	1,169	1,017	127	—
Total payables	5,379	4,575	3,768	2,948	1,798	+31.5%
Short-term debt	1,635	5,117	6,905	1,501	1,538	+1.5%
Tax payables	5,875	0	3,849	475	127	+160.8%
Other current liabilities	28,214	7,145	4,932	3,905	10,683	+27.5%
Total current liabilities	35,228	28,377	27,293	17,138	15,053	+23.7%
Non-current liabilities
Long-term debt	40,868	28,527	18,321	14,738	15,346	+27.7%
Deferred tax liabilities (non-current)	0	0	0	87	1,734	—
Other non-current liabilities	9,845	7,540	7,529	6,751	7,518	+7.0%
Total non-current liabilities	50,713	36,067	25,849	21,576	24,599	+19.8%
Total debt	42,503	33,644	25,225	16,239	16,885	+26.0%
Total liabilities	85,941	64,443	53,143	38,714	39,651	+21.3%
Stockholders' equity
Common stock	590	592	594	594	596	-0.3%
Retained earnings	24,470	13,545	10,312	10,043	8,959	+28.6%
Additional paid-in capital	7,346	7,439	7,250	6,921	6,833	+1.8%
Treasury stock	0	(49)	(44)	(50)	(53)	—
Accumulated other comprehensive income (loss)	(2,880)	(4,322)	(4,327)	(3,845)	(4,343)	—
Other stockholders' equity	(2,991)	(3,013)	(3,013)	(3,013)	(3,013)	—
Total stockholders' equity	26,535	14,192	10,772	10,650	8,979	+31.1%
Total equity	26,535	14,272	10,864	10,775	9,155	+30.5%
Minority interest	0	80	92	126	176	—
Total liabilities & equity	112,476	78,715	64,006	49,490	48,806	+23.2%
Additional fields
Accrued Expenses	0	11,539	11,689	8,784	1,034	—
Net Debt	35,340	30,376	22,407	14,172	13,066	+28.2%
Total Investments	2,907	3,371	3,161	3,047	3,303	-3.1%

Eli Lilly and Company

LLYNYSE

$1,294.35

Last price · USD

Market cap: $1.16T
P/E: 56.4x
EV / EBITDA: 37.8x
P/S: 17.8x
FCF yield: 0.8%
Div. yield: 0.46%

Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.

Eli Lilly and Company balance sheet

Annual · USD millions except per-share data · 45 lines

Fiscal year	2025latest	2024	2023	2022	2021	CAGR
Current assets
Cash & cash equivalents	7,163	3,268	2,819	2,067	3,819	+17.0%
Short-term investments	105	155	109	145	90	+3.9%
Cash & short-term investments	7,268	3,423	2,928	2,212	3,909	+16.8%
Net receivables	20,155	13,275	11,336	8,559	8,127	+25.5%
Accounts receivable	17,760	11,006	9,091	6,896	6,673	+27.7%
Other receivables	2,395	2,270	2,246	1,663	1,454	+13.3%
Inventory	13,744	7,589	5,773	4,310	3,886	+37.1%
Prepaids	14,315	8,341	5,541	2,947	2,531	+54.2%
Other current assets	147	111	150	7	0	—
Total current assets	55,629	32,740	25,727	18,035	18,452	+31.8%
Non-current assets
Property, plant & equipment (net)	24,675	17,102	12,914	10,144	8,985	+28.7%
Goodwill	5,898	5,770	4,940	4,073	3,892	+11.0%
Intangible assets	6,521	6,166	6,907	7,207	7,692	-4.0%
Goodwill & intangible assets	12,419	11,937	11,846	11,280	11,584	+1.8%
Long-term investments	2,802	3,216	3,052	2,902	3,213	-3.4%
Tax assets	9,959	8,001	5,477	2,793	2,489	+41.4%
Other non-current assets	6,992	5,720	4,990	4,337	4,083	+14.4%
Total non-current assets	56,847	45,975	38,279	31,455	30,354	+17.0%
Total assets	112,476	78,715	64,006	49,490	48,806	+23.2%
Current liabilities
Accounts payable	5,379	3,229	2,599	1,931	1,671	+34.0%
Other payables	0	1,346	1,169	1,017	127	—
Total payables	5,379	4,575	3,768	2,948	1,798	+31.5%
Short-term debt	1,635	5,117	6,905	1,501	1,538	+1.5%
Tax payables	5,875	0	3,849	475	127	+160.8%
Other current liabilities	28,214	7,145	4,932	3,905	10,683	+27.5%
Total current liabilities	35,228	28,377	27,293	17,138	15,053	+23.7%
Non-current liabilities
Long-term debt	40,868	28,527	18,321	14,738	15,346	+27.7%
Deferred tax liabilities (non-current)	0	0	0	87	1,734	—
Other non-current liabilities	9,845	7,540	7,529	6,751	7,518	+7.0%
Total non-current liabilities	50,713	36,067	25,849	21,576	24,599	+19.8%
Total debt	42,503	33,644	25,225	16,239	16,885	+26.0%
Total liabilities	85,941	64,443	53,143	38,714	39,651	+21.3%
Stockholders' equity
Common stock	590	592	594	594	596	-0.3%
Retained earnings	24,470	13,545	10,312	10,043	8,959	+28.6%
Additional paid-in capital	7,346	7,439	7,250	6,921	6,833	+1.8%
Treasury stock	0	(49)	(44)	(50)	(53)	—
Accumulated other comprehensive income (loss)	(2,880)	(4,322)	(4,327)	(3,845)	(4,343)	—
Other stockholders' equity	(2,991)	(3,013)	(3,013)	(3,013)	(3,013)	—
Total stockholders' equity	26,535	14,192	10,772	10,650	8,979	+31.1%
Total equity	26,535	14,272	10,864	10,775	9,155	+30.5%
Minority interest	0	80	92	126	176	—
Total liabilities & equity	112,476	78,715	64,006	49,490	48,806	+23.2%
Additional fields
Accrued Expenses	0	11,539	11,689	8,784	1,034	—
Net Debt	35,340	30,376	22,407	14,172	13,066	+28.2%
Total Investments	2,907	3,371	3,161	3,047	3,303	-3.1%